License and Royalty Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Schedule Of License and Royalty Revenue

License and royalty revenue consisted of the following (in thousands):

	Years Ended December 31,
	2021		2020		2019
AbbVie collaboration and license agreement	$	370,000	$	—	$	—
Royalties on net sales of Zolgensma		94,978		61,631		20,829
Achievement of sales-based milestone for Zolgensma		—		80,000		—
Other license and royalty revenue		5,369		12,936		14,404
Total license and royalty revenue	$	470,347	$	154,567	$	35,233

Novartis Gene Therapies [Member]

Schedule Of License and Royalty Revenue

The Company recognized the following amounts under the March 2014 License with Novartis Gene Therapies (in thousands):

	Years Ended December 31,
	2021		2020		2019
Royalties on net sales of Zolgensma	$	94,978	$	61,631	$	20,829
Achievement of sales-based milestone for Zolgensma		—		80,000		—
Other license revenue		—		3,500		3,500
Total license and royalty revenue	$	94,978	$	145,131	$	24,329
Interest income from licensing	$	22	$	26	$	29